

Exciting news!

Your expectant patient is interested in Prequel® Prenatal Screen to learn more about the health of their pregnancy and their baby.

Visit our website
and read along
to learn more.



What is Prequel?

Prequel provides patients with early genetic insights into the baby's development and the health of the pregnancy. This prenatal cell-free DNA (cfDNA) screen can assess if a pregnancy is at an increased risk for a wide variety of chromosomal conditions like Down, Edwards, or Patau syndromes.

Standard panel

Common Aneuploidy

- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)

Opt-in

Sex Chromosome Analysis

- Monosomy X (Turner syndrome)
- Klinefelter syndrome (XXY)
- Trisomy X (XXX)
- XYY syndrome
- Male (XY)
- Female (XX)

Opt-in

Microdeletions

- 22q11.2 deletion (DiGeorge syndrome)
- 1p36.1 deletion syndrome
- 15q11 deletions (Angelman or Prader-Will syndrome)
- 4p deletion (Wolf-Hirschhorn syndrome)
- 5p deletion (Cri-du-Chat syndrome)

Opt-in

Expanded Aneuploidy Analysis (EAA)


Expands aneuploidy analysis to include all 22 autosomes. Associated conditions include:

- Placental insufficiency (e.g. growth restriction, stillbirth)
- Uniparental disomy syndromes (e.g. Prader-Will, Beckwith-Wiedemann)
- Fetal syndromes (e.g. Trisomy 8, Trisomy 22)

Why Prequel?

Prequel with AMPLIFY™ technology selectively enriches fetal fraction (FF) by 2.3X on average for every patient, even patients with high BMI, increasing confidence in the results and reducing the chance of a sample failure.^{1,2}

Consider this scenario. Which prenatal screen will you choose to provide the best care possible for this patient?



Less than 4% FF presents a sample failure risk which may prompt a redraw

AMPLIFY increases FF by 2.3X on average delivering results to 99.9% of all patients at 10 weeks, even those with high BMI³

Why should I order Prequel for my patient?

Most pregnancies are at low-risk for chromosomal abnormalities. However, in the rare case of a high-risk result, patients have time to:

- Explore diagnostic testing
- Consult a specialist
- Find the right delivery facility
- Join a support group

Dedicated to making prenatal screening available to every patient



Financial Assistance

Myriad understands that every situation is unique. Our financial assistance program considers each patient's ability to pay, collaborating with them directly to find the best option.



Expert Support

We want you to have all the support you need. Every Prequel Prenatal Screen includes scheduled or on-demand consultations with our board-certified genetic counselors who are available to answer clinical questions your patient may have.



Offered as early as 10 weeks gestational age, even for those with high BMI



Results available in
7-10 days



Prequel® with AMPLIFY™ technology enables results for 99.9% of all patients regardless of BMI³

About Myriad Genetics

Myriad's prenatal screens offer healthcare providers the most reliable answer possible.

Each of our prenatal genetic screens delivers clear, actionable results and easy to-understand reports to ensure that both, patients and their healthcare providers, can use the information to guide important healthcare decisions.



50% of pregnant women present with high BMI.⁵ Patients with high BMI may have lower fetal fraction in cell-free DNA (cfDNA) screening potentially resulting in a sample failure.²

1. Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. *Genet Med* 23, 443–450 (2021). 2. Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. *Prenat Diagn.* 2020;40(3):333-341. doi:10.1002/pd.5603. 3. Hancock S, Ben-Shachar R, Adusei C, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. *Ultrasound Obstet Gynecol.* 2020;56(3):422-430. doi:10.1002/uog.21904. 4. Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. *Prenat Diagn.* 2020;40(3):333-341. doi:10.1002/pd.5603. 5. Deputy NP, Dub B, Sharma AJ. Prevalence and Trends in Prepregnancy Normal Weight - 48 States, New York City, and District of Columbia, 2011-2015. *MMWR Morb Mortal Wkly Rep.* 2018;66(51-52):1402-1407. Published 2018 Jan 5. doi:10.15585/mmwr.mm665152a3.